# Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

> **NCT05369000** · PHASE1 · TERMINATED · sponsor: **Lava Therapeutics** · enrollment: 96 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** LAVA-1207
- **BIOLOGICAL:** LAVA-1207 plus Pembrolizumab

## Key facts

- **NCT ID:** NCT05369000
- **Lead sponsor:** Lava Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-17
- **Primary completion:** 2025-06-18
- **Final completion:** 2025-06-18
- **Target enrollment:** 96 (ACTUAL)
- **Why stopped:** The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2).
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05369000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05369000, "Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05369000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*